Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia: NICE technology appraisal guidance

Heart

Volumn 94, Issue 5, 2008, Pages 642-643

  Charles, Z ^a   Pugh, E ^a   Barnett, D ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 42549113872     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.138263     Document Type: Short Survey

References (5)

1. National Institute for Health and Clinical Excellence. Ezetimibe for primary (heterozygous-familial and non-familial) hypercholesterolemia. NICE technology appraisal guidance. London: National Institute for Health and Clinical Excellence, 2007: No 132. Available from http://guidance.nice.org. uk/TA132 (accessed 13 February 2008).
2. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence, 2004 Available from http:// www.nice.org.uk/niceMedia/pdf/ TAP_Methods.pdf (accessed 13 February 2008).
3. Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia. December 2006. Available at http://www.nice.org.uk/guidance/index.jsp7action=folder&0=35120 (accessed 15 February 2008).
4. Ara R, Tumur I, Pandor A, et al. Amendments to methodologies used to apply the effectiveness of ezetimibe co-administration, April 2007. Available at http://www.nice.org.uk/guidance/index.jsp?action= folder&0=35120 (accessed 15 February 2008).
5. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. NICE technology appraisal guidance. London: National Institute for Health and Clinical Excellence, 2006: No 94. Available from: http://www.nice.org.uk/TA094 (accessed 13 February 2008).